Top Human Milk Oligosaccharides (HMO) Companies

Human Milk Oligosaccharides (HMO) Market size was valued at USD 229.64 Million in 2024 and is poised to grow from USD 253.3 Million in 2025 to USD 554.93 Million by 2033, growing at a CAGR of 10.3% during the forecast period (2026–2033).

The human milk oligosaccharides (HMO) market is very competitive, with both well-established manufacturers and creative entrants vying for market share as demand for HMO-fortified products rises. Prominent competitors include DuPont Nutrition & Biosciences, Nestlé S.A., Glycosyn LLC, Jennewein Biotechnologie GmbH, and Elicityl owing to their experience producing HMOs, their capacity for extensive research, and their established relationships in the infant nutrition and functional foods industries. 'DSM (Netherlands)', 'BASF SE (Germany) ', 'DuPont (US) ', 'Nestle (Switzerland) ', 'Inbiose NV (Belgium) ', 'Gnubiotics Sciences S.A (Switzerland) ', 'Abbott Laboratories (US) ', 'Royal FrieslandCampina N.V (Netherlands) ', 'Elicityl S.A (France) ', 'Dextra Laboratories (UK) ', 'Glycom A/S (Denmark) ', 'Glycosyn (US) ', 'Medolac Laboratories (US) ', 'Neolacta Lifesciences Pvt. Ltd. (India) ', 'Jennewein Biotechnologie GmbH (Germany) ', 'Lonza Specialty Ingredients (Switzerland) ', 'Kirin Holdings Company (Kyowa Hakko Bio) (Japan) ', 'ZuChem Inc. (US)'

The growing awareness of the advantages of human milk oligosaccharides (HMOs) for health is an important driver . Demand for HMO-fortified goods has increased as a result of the role that HMOs play in promoting the immune system, cognitive development, and gut health of infants as well as possible benefits for adults.

Expanding Applications Beyond Infant Nutrition: Although HMOs have historically been linked to baby feeding and are found naturally in breast milk, there is a rising movement to investigate their potential in other contexts. HMOs are being researched for use in functional foods, dietary supplements, and even medications to treat a range of health issues in people of different ages.

The human milk oligosaccharides (HMO) market showed notable regional variations, with North America having the largest market share. North America's advanced baby feeding business, robust research capacity, and increasing consumer demand for HMO-fortified goods are the reasons for its dominance. The notable use of HMOs in infant formula and related products can be attributed to the region's focus on ensuring optimal infant health and development.